AVITA Medical Analyst Price Targets - Benzinga

AVITA Medical Inc

RCELNASDAQ

Trade with Public

Trade with Public

$11.20

0.262.38%

At close: Sep 4, 5:00 PM EST

$11.23

0.030.27%

After Hours: Sep 4, 6:20 PM EST

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

AVITA Medical Analyst Price Targets

Wall Street analyst price targets and consensus rating for AVITA Medical (RCEL).

Price Target Range — 13 Quarters

Analyst Consensus — 7 Analysts

6Buy

1Hold

Consensus RatingBuy# Analysts7Avg. Consensus PT$12Upside to Avg. PT+9.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 28, 2026	Lake Street	Frank Takkinen	PT Raise	Buy	$8→$12
Aug 19, 2026	TD Cowen	Joshua Jennings	PT Raise	Buy	$12→$14
Aug 19, 2026	BTIG	Ryan Zimmerman	PT Raise	Buy	$7→$11
Aug 7, 2026	BTIG	Ryan Zimmerman	Upgrade	Neutral→Buy	$7
May 15, 2026	Lake Street	Frank Takkinen	Upgrade	Hold→Buy	$4→$6
Apr 9, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$10
Apr 8, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$10
Mar 5, 2026	Northland Capital Markets	Carl Byrnes	Initiate	Outperform	$10
Feb 17, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$10
Jan 26, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$10
Jan 16, 2026	Lake Street	Frank Takkinen	PT Raise	Hold	$3→$4
Jan 15, 2026	D. Boral Capital	Jason Kolbert	PT Cut	Buy	$14→$10
Nov 20, 2025	BTIG	Ryan Zimmerman	Upgrade	Sell→Neutral	—
Nov 7, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$14
Oct 17, 2025	Lake Street	Frank Takkinen	Downgrade	Buy→Hold	$8→$4
Oct 17, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$14
Sep 15, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$14
Sep 5, 2025	D. Boral Capital	Jason Kolbert	PT Cut	Buy	$18→$14
Aug 11, 2025	Lake Street	Brooks O'Neil	PT Cut	Buy	$14→$8
Aug 8, 2025	D. Boral Capital	Jason Kolbert	PT Cut	Buy	$19→$18

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
TD Cowen Maintains Buy on AVITA Medical, Raises Price Target to $14

TD Cowen analyst Joshua Jennings maintains AVITA Medical (NASDAQ:RCEL) with a Buy and raises the price target from $12 to $14.

Benzinga Newsdesk

PRO
BTIG Maintains Buy on AVITA Medical, Raises Price Target to $11

BTIG analyst Ryan Zimmerman maintains AVITA Medical (NASDAQ:RCEL) with a Buy and raises the price target from $7 to $11.

Benzinga Newsdesk

This SpaceX Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

Wall Street analysts upgraded AVITA, Etsy, Unity, and raised target prices for these stocks. See what others think before buying Unity.

Avi Kapoor

PRO
BTIG Upgrades AVITA Medical to Buy, Announces $7 Price Target

BTIG analyst Ryan Zimmerman upgrades AVITA Medical (NASDAQ:RCEL) from Neutral to Buy and announces $7 price target.

Benzinga Newsdesk

PRO
Lake Street Upgrades AVITA Medical to Buy, Raises Price Target to $6

Lake Street analyst Frank Takkinen upgrades AVITA Medical (NASDAQ:RCEL) from Hold to Buy and raises the price target from $3.5 to $6.

Benzinga Newsdesk

PRO
Northland Capital Markets Initiates Coverage On AVITA Medical with Outperform Rating, Announces Price Target of $10

Northland Capital Markets analyst Carl Byrnes initiates coverage on AVITA Medical (NASDAQ:RCEL) with a Outperform rating and announces Price Target of $10.

Benzinga Newsdesk